AHA today urged the Food and Drug Administration to take “any and all steps possible” to resolve worsening shortages of small-volume parenteral solutions that are fundamental to patient care in hospitals. “We are concerned that the shortages of widely-used and critical products are quickly becoming a crisis and looming threat to the public’s health,” wrote AHA Executive Vice President Tom Nickels. “Therefore, we call on the FDA to vigorously pursue strategies with the current manufacturers of these products and to seek out new suppliers in order to ameliorate the current shortage, as well as prevent such shortages from occurring in the future.” Current shortages of small-volume parenteral solutions include 50 and 100 milliliter injection bags of sodium chloride 0.9%, dextrose 5% and intravenous nutritional products.

Related News Articles

Headline
The AHA June 7 submitted comments on a discussion draft of the Drug Shortage Prevention and Mitigation Act, bipartisan legislation proposing to provide…
Blog
The inability of many patients to obtain needed drug therapies due to either high prices or shortages has negatively affected patient outcomes.1 Nearly 30% of…
Headline
ASHP tracked a record 323 active drug shortages during the first quarter of 2024, surpassing the previous record of 320 shortages in 2014.“Some of the most…
Headline
The Department of Health and Human Services April 2 released a white paper proposing policy solutions for Congress and others to prevent drug shortages and…
Headline
In a statement submitted to the House Ways and Means Committee for a hearing Feb. 6 on chronic drug shortages, AHA recommended Congress enact legislation to…
Headline
Reps. Doris Matsui, D-Calif., and Larry Bucshon, R-Ind., Jan. 12 introduced a House version of the Mapping America’s Pharmaceutical Supply Act, legislation…